Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as Lepodisiran Sodium
Lepodisiran · 3 trials · 7 indications
Time to first event in a MACE-4 composite endpoint, comprised of cardiovascular death, nonfatal myocardial infarction, nonfatal ischemic stroke, and urgent coronary revascularization.
PK: AUC of Lepodisiran
PK: Cmax of Lepodisiran
| Arm | Type | Description |
|---|---|---|
| Lepodisiran | EXPERIMENTAL | Participants will receive lepodisiran subcutaneously (SC) |
| Placebo | PLACEBO_COMPARATOR | Participants will receive placebo SC |
| Lepodisiran Sodium | EXPERIMENTAL | Lepodisiran sodium administered subcutaneously (SC). |
| Lepodisiran Group 1 | EXPERIMENTAL | Lepodisiran administered subcutaneously (SC) |
| Lepodisiran Group 2 | EXPERIMENTAL | Lepodisiran administered SC |
| Lepodisiran Group 3 | EXPERIMENTAL | Lepodisiran administered SC |
| Lepodisiran Group 4 | EXPERIMENTAL | Lepodisiran administered SC |
| Name | Type | Description |
|---|---|---|
| Lepodisiran | DRUG | Administered SC |
| Placebo | DRUG | Administered SC |
| Lepodisiran Sodium | DRUG | Administered SC |
Inclusion Criteria: * Have an Lp(a) ≥175 nmol/L * Have established cardiovascular (CV) disease or are at risk for a first CV event * Have angiographic evidence of coronary artery disease on screening CCTA * If taking lipid-lowering medications, inclusive of statins or prescription strength niacin a...
Lepodisiran is an investigational small molecule being studied for cardiovascular conditions including atherosclerotic cardiovascular disease (ASCVD), atherosclerosis, and elevated lipoprotein(a). It is also being evaluated in a liver function study. The drug is in Phase 3 clinical development and is not yet approved by regulatory authorities.
Lepodisiran is a small interfering RNA (siRNA) agent, as indicated by its '-siran' suffix. It is designed to target and reduce elevated lipoprotein(a) levels, which are associated with increased cardiovascular risk. The drug is being investigated for its potential to lower Lp(a) and reduce major adverse cardiovascular events.
Lepodisiran is being developed by Eli Lilly and Company, a pharmaceutical company traded on the New York Stock Exchange under the ticker symbol LLY. The company is conducting clinical trials to evaluate the drug's safety and efficacy for cardiovascular indications.
Lepodisiran is currently in Phase 3 clinical development. It is being studied in two Phase 3 trials, including the ACCLAIM-Lp(a) trial and a coronary plaque reduction study. The drug is investigational and has not received FDA approval.
Lepodisiran is being evaluated in three clinical trials. The Phase 3 ACCLAIM-Lp(a) trial (NCT06292013) enrolls 17,300 adults with ASCVD and elevated Lp(a). A second Phase 3 trial (NCT07613294) studies plaque reduction in 252 adults. A completed Phase 1 trial (NCT06916078) assessed liver function effects.
Yes, Lepodisiran is also known as Lepodisiran Sodium. Both names refer to the same investigational drug being developed by Eli Lilly and Company for cardiovascular conditions associated with elevated lipoprotein(a).